Innovent Biologics, Inc. (1801.HK)
HKD 36.2
(-0.82%)
HKD 36.2
(-0.82%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 6.2 Billion | 4.55 Billion | 4.26 Billion | 3.84 Billion | 1.04 Billion | 9.47 Million |
| Cost of Revenue | 1.8 Billion | 930.99 Million | 573.04 Million | 387.76 Million | 124.87 Million | -1.31 Million |
| Gross Profit | 4.39 Billion | 3.62 Billion | 3.69 Billion | 3.45 Billion | 922.64 Million | 10.78 Million |
| Operating Expenses | 5.06 Billion | 6.2 Billion | 6.04 Billion | 3.49 Billion | 2.7 Billion | 1.56 Billion |
| Selling, General and Administrative Expenses | 3.85 Billion | 3.42 Billion | 3.61 Billion | 1.77 Billion | 1.44 Billion | 413.5 Million |
| Research and Development Expenses | 2.22 Billion | 2.87 Billion | 2.47 Billion | 1.85 Billion | 1.29 Billion | 1.22 Billion |
| Other Expenses | - | -90.19 Million | -45.12 Million | -130.68 Million | -41.38 Million | -4.33 Billion |
| Cost and Expenses | 7.88 Billion | 7.13 Billion | 6.61 Billion | 3.88 Billion | 2.82 Billion | 1.56 Billion |
| Operating Income | -1.67 Billion | -2.07 Billion | -3.11 Billion | -820.13 Million | -1.66 Billion | -1.78 Billion |
| Interest Expense | 98.62 Million | 101.69 Million | 62.46 Million | 68.35 Million | 59.49 Million | 68.96 Million |
| Income Tax Expense | -116.49 Million | 8.8 Million | 87.03 Million | 139.7 Million | 56.86 Million | 27.47 Million |
| Earnings before Tax | -1.14 Billion | -2.17 Billion | -3.05 Billion | -858.71 Million | -1.71 Billion | -5.87 Billion |
| Net Income | -1.02 Billion | -2.17 Billion | -3.13 Billion | -998.42 Million | -1.77 Billion | -5.77 Billion |
| Earnings Per Share Basic | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 |
| Earnings Per Share Diluted | -0.66 | -1.46 | -2.16 | -0.74 | -1.51 | -17.24 |
| Weighted Average Shares Outstanding | 1.55 Billion | 1.49 Billion | 1.45 Billion | 1.34 Billion | 1.17 Billion | 334.68 Million |
| Weighted Average Shares Outstanding (Diluted) | 1.55 Billion | 1.49 Billion | 1.45 Billion | 1.35 Billion | 1.17 Billion | 334.68 Million |
| Gross Margin | 0.71 | 0.80 | 0.87 | 0.90 | 0.88 | 1.14 |
| EBIT Margin | -0.11 | -0.39 | -0.68 | -0.19 | -1.51 | -605.86 |
| Profit Margin | -0.17 | -0.48 | -0.73 | -0.26 | -1.70 | -609.00 |
| EBITDA | -660.68 Million | -1.74 Billion | -2.37 Billion | -704.73 Million | -1.57 Billion | -5.73 Billion |
| Earnings Before Tax Margin | -0.27 | -0.46 | -0.73 | -0.21 | -1.59 | -188.42 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 1.97 Billion | 1.97 Billion | 6.2 Billion | 1.75 Billion | 1.75 Billion | 1.35 Billion |
| Cost of Revenue | 547.19 Million | 547.19 Million | 1.13 Billion | 512.54 Million | 512.54 Million | 390.87 Million |
| Gross Profit | 1.42 Billion | 1.42 Billion | 5.06 Billion | 1.23 Billion | 1.23 Billion | 959.88 Million |
| Operating Expenses | 1.79 Billion | 1.79 Billion | 5.97 Billion | 1.71 Billion | 1.88 Billion | 1.06 Billion |
| Selling, General and Administrative Expenses | 1.09 Billion | 1.09 Billion | - | 1.06 Billion | 1.06 Billion | 857.9 Million |
| Research and Development Expenses | 699.71 Million | 699.71 Million | - | 652.36 Million | 652.36 Million | 461.4 Million |
| Other Expenses | - | - | -680.09 Million | - | - | - |
| Cost and Expenses | 2.34 Billion | 2.34 Billion | 7.11 Billion | 2.23 Billion | 2.39 Billion | 1.45 Billion |
| Operating Income | -370.34 Million | -370.34 Million | -1.67 Billion | -480.22 Million | -422.54 Million | -359.42 Million |
| Interest Expense | - | - | 98.62 Million | - | - | - |
| Income Tax Expense | 17.5 Thousand | 17.5 Thousand | -116.49 Million | 231 Thousand | 231 Thousand | 58.48 Million |
| Earnings before Tax | -196.29 Million | -196.29 Million | -1.14 Billion | -444.15 Million | -444.15 Million | -128.05 Million |
| Net Income | -196.31 Million | -196.31 Million | -1.02 Billion | -444.38 Million | -444.38 Million | -69.57 Million |
| Earnings Per Share Basic | -0.12 | -0.12 | - | -0.28 | -0.28 | -0.05 |
| Earnings Per Share Diluted | -0.12 | -0.12 | - | -0.28 | -0.28 | -0.05 |
| Weighted Average Shares Outstanding | 1.62 Billion | 1.62 Billion | 1.55 Billion | 1.57 Billion | 1.57 Billion | 1.53 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.62 Billion | 1.62 Billion | 1.55 Billion | 1.58 Billion | 1.58 Billion | 1.53 Billion |
| Gross Margin | 0.72 | 0.72 | 0.82 | 0.71 | 0.71 | 0.71 |
| EBIT Margin | -0.06 | -0.06 | - | -0.21 | -0.21 | -0.20 |
| Profit Margin | -0.10 | -0.10 | -0.17 | -0.25 | -0.25 | -0.05 |
| EBITDA | -124.43 Million | -124.43 Million | - | -370.87 Million | -370.87 Million | -273.29 Million |
| Earnings Before Tax Margin | -0.19 | -0.19 | -0.27 | -0.27 | -0.24 | -0.27 |
0QW7
CCB
ARTNA
DUFRY
0I4X
2186